Alison Sehgal, MD - The Case for CAR T-Cell Therapy in Second-Line R/R LBCL: A Framework for Long-Term Success

Edward B. Garon, MD, MS - A Case of Best Practices: Optimizing First-Line Chemoimmunotherapy for Advanced Squamous NSCLC

Luis Paz-Ares, MD, PhD / Kristin Higgins, MD - Creating a Roadmap to Optimize Care for Patients With LS-SCLC: Integrating the Evidence Into Practical Care

Sonia Pernas, MD, PhD / Joyce O'Shaughnessy, MD / Hans Wildiers, MD, PhD - Case-Based Insights Into HER2-Low and -Ultralow Metastatic Breast Cancer: Elevating Patient Outcomes With ADCs

Pasi A. Jänne, MD, PhD, FASCO - Translating the Latest Evidence on First-Line Treatment for EGFR-Mutated NSCLC Into Practice: An Update for Community Clinicians

Barbara Melosky, MD, FRCPC / Hossein Borghaei, DO, MS - Towards Durable Outcomes: Personalizing Frontline Immunotherapy-Based Regimens in Advanced NSCLC

Andrew M. Brunner, MD - FLT3 Inhibitors in Action: Clinical Case Challenges in Newly Diagnosed AML

Justin F. Gainor, MD - A Blueprint for Action: Integrating Pre- and/or Post-Operative Immunotherapy Into Early-Stage NSCLC Management

Ramez N. Eskander, MD - Selecting the Optimal Regimen for Advanced Endometrial Cancer: A Case-Based, Multidisciplinary Approach

Kathleen Moore, MD, MS, FASCO, Debra Richardson, MD - Current and Future Treatment of Platinum-Resistant Ovarian Cancer With ADCs: Implications of Targeting CDH6

Ticiana Leal, MD / Neal Ready, MD, PhD - From Cases to Care: Personalizing First-Line Immunotherapy in Advanced NSCLC Through a Patient-Centered Approach

Nikhil I. Khushalani, MD - From Trial to Team: Optimizing Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma

David Rees, MA, MBBS, FRCPath, FRCPCH, FRCP - Sickle Cell Disease in Perspective: An Expert Point of View on Therapeutic Selection and Comprehensive Care

Mona Shafey, MD, FRCPC / Nicole Lamanna, MD - Charting the Course: Navigating the Maze of Treatment Selection and Sequencing in CLL

Raffaele Califano, MD / Nicolas Girard, MD, PhD / Antonio Passaro, MD, PhD - Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

Jesus Berdeja, MD - Chartering New Frontiers in Myeloma Care: What Role May Novel CELMoDs Play in Early-Relapse Therapy?

Sebastian Stintzing, MD - A Step-by-Step Guide to Metastatic CRC: Strategies to Integrate Anti-EGFR Therapies

Daniel Petrylak, MD - Answering Key Questions About Biomarkers in Urothelial Cancer: Guidance for Improving Implementation

Benjamin Levy, MD, FASCO - Keeping Pace With TROP2-Directed ADCs: Their Evolving Role in Advanced, Pretreated EGFR-Mutated NSCLC

Luis Paz-Ares, MD, PhD / Niels Reinmuth, MD, PhD - Developing a Master Plan for ES-SCLC: A Practical Guide to Elevate Care in the Real-World